FDA Approves Subcutaneous Induction for AbbVie's Skyrizi in Crohn's Disease

Bitget2026/10/23 19:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

U.S. FDA approved subcutaneous induction dosing of AbbVie's Skyrizi for adults with moderately to severely active Crohn's disease.
The regimen allows patients to begin treatment at home using an on-body injector, then continue maintenance dosing every eight weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610231533PR_NEWS_USPR_____CG77917) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FDA Approves Subcutaneous Induction for AbbVie's Skyrizi in Crohn's Disease

You may also like

Crypto prices